FDA Approves Sugammadex Sodium for Gland Pharma
The FDA has approved Sugammadex Sodium under application ANDA214364 submitted by Gland Pharma.
Therapeutic Area
Therapeutic area intelligence for Reversal Agent with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.